Ipsen and GENFIT Enter Into Exclusive Licensing Agreement fo

Agreement gives Ipsen global rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational

Related Keywords

Paris , France General , France , Saclay , Taiwan , Shanghai , China , Schattenberg , Sachsen , Germany , United States , Hong Kong , Cambridge , Cambridgeshire , United Kingdom , Macau , American , Fanny Allaire , Pascal Prigent , Jess Smith , David Loew , Ipsen Euronext , Global Communications , European Commission , Uncertainties Of The Company , Drug Administration , Terns Pharmaceuticals , Nasdaq , Exchange Commission , Head Of Global Communications , European Medicines Agency , Euronext , Stephanie Boyer , Business Development , Primary Biliary Cholangitis , Breakthrough Therapy Designation , Orphan Drug Designation , Chief Executive Officer , Biliary Cholangitis , Breakthrough Therapy , Rare Disease , Consumer Healthcare , Total Sales , Sponsored Leveli American Depositary Receipt , Chronic Liver Failure , Nasdaq Global Select Market , French Autorit , Des March , Private Securities Litigation Reform Act , Registration Document , Transplantation Hepatology , Investor Relations , Relations Manager , Communications Director , Boyer Press , Lipsen , Genfit , Winter , Into , Exclusive , Icensing , Agreement , Elafibranor , Hase , Sset , Revaluated , Primary , Miliary , Cholangitis , Art , Song , Term , Lobal , Partnership ,